Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial

What Was Tested

The paper reports a study of Semaglutide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

The researchers aimed to assess whether a 6-week subcutaneous infusion of GIP alone and in combination with the GLP-1 receptor agonist semaglutide would enhance glycaemic control in individuals with type 2 diabetes.

Why It Was Studied

The long-term glycaemic effects of glucose-dependent insulinotropic polypeptide (GIP) remain unclear.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Participants were randomly assigned (1:1:1:1), using a block randomisation list, to receive either placebo plus placebo, placebo plus GIP, semaglutide plus placebo, or semaglutide plus GIP (all self-administered subcutaneously).

Participants and investigators were masked to treatment assignment.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

This single-centre, double-blind, parallel-group, randomised, placebo-controlled trial was conducted at the Center for Clinical Metabolic Research (Hellerup, Denmark).

This study is registered at ClinicalTrials.gov, NCT05078255 (completed).

What Was Measured

The subject headings attached to it are Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Infusions, Subcutaneous, Hypoglycemic Agents and Blood Glucose.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide and GIP (Gastric Inhibitory Polypeptide).

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Semaglutide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.